(Abst.) Association of body mass index and clinical response in MS patients receiving ofatumumab on: March 07, 2025, 07:00:57 am #1 From PubMed (March 7, 2025)--"Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis": Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis - PubMed Inflammatory disease outcomes did not differ but disability progression was more frequent in the highest BMI quartile (BMI >29.2 kg/m<sup>2</sup>). This was associated with lower ofa... PubMed · pubmed.ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
